Clinical efficacy of Thalidomide combined with PAD Regimen in patients with multiple Myeloma

To evaluate the clinical efficacy of thalidomide combined with PAD regimen in patients with multiple myeloma (MM).

It was a Clinical comparative study. A total of 120 patients with MM were admitted at Beijing Aerospace General Hospital from September 2020 to June 2022 randomly divided into two groups, with 60 patients in each group. The study group was treated with thalidomide combined with a PAD regimen (bortezomib, doxorubicin and dexamethasone), while the control group with a PAD regimen alone. After treatment, the therapeutic effect, adverse drug reactions, bone metabolic markers such as serum alkaline phosphatase (ALP) and osteocalcin (OCN) before and after treatment, as well as T-lymphocyte subsets CD3⁺, CD4⁺, CD8⁺ and CD4⁺/CD8⁺ levels before and after treatment were compared and analyzed between the two groups.

The total efficacy in the study group was 90%, which was significantly higher than 70% in the control group (p= 0.00). The incidence of adverse drug reactions was 40% in the study group and 38% in the control group, without statistically significant difference (p= 0.85). After treatment, ALP and OCN levels in the study group were significantly higher than those in the control group (ALP, p= 0.01; OCN, p= 0.00), and CD3⁺, CD4⁺ and CD4⁺/CD8⁺ in the study group also increased significantly compared with those in the control group (CD3⁺, p= 0.02; CD4⁺, p= 0.00; CD4⁺/CD8⁺, p= 0.00).

Thalidomide combined with a PAD regimen is definitely effective in patients with MM, it can obviously improve immune function and bone salt metabolism, with no increase in adverse reactions but high safety and effectiveness.